ArticleNeurology research international2012
Current trends in targeted therapies for glioblastoma multiforme.
Article in Neurology research international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 1 synthesis or guideline pooled it, 199 citations in OpenAlex.
- A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion.Molecular neurobiology · 2013Pooled it
- Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients.Journal of neuro-oncology · 2019Trial
- BBB-aware stimuli-responsive and biomimetic nanomedicines for glioblastoma.Chinese neurosurgical journal · 2026Review
- Emerging Perspectives on Adverse Childhood Experiences and Brain Cancer Immunotherapy.Cancers · 2026Article
- Conducting a randomized controlled clinical trial on palliative care in patients with glioblastoma - what are the challenges?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Exploring metabolic signatures in urine using NMR for improved prognosis of gliomas.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Identification of an age-related monocyte-derived macrophages characteristic genes-based signature for high-grade diffuse glioma.Scientific reports · 2026Article
- Management of persistent residual growth of high-grade glioma: a case report highlighting clinical and therapeutic challenges.Oxford medical case reports · 2025Article
- Emerging trends in cell-based therapies: contemporary advances and ethical considerations in translational neurosurgical oncology.Journal of neuro-oncology · 2025Review
- Role of PDGFRα-mediated signalling in anoikis resistance in glioblastoma: in vitro study.In vitro cellular & developmental biology. Animal · 2025Article
- Impact of High-Grade Glioma Lesion Location on Preoperative Neuropsychological Deficits.Cancers · 2025Article
- Review
- Role of Amide Proton Transfer Weighted MRI in Predicting MGMTp Methylation Status, p53-Status, Ki-67 Index, IDH-Status, and ATRX Expression in WHO Grade 4 High Grade Glioma.Tomography (Ann Arbor, Mich.) · 2025Article
- Article
- Mitochondrial DNA copy number alterations: Key players in the complexity of glioblastoma (Review).Molecular medicine reports · 2025Review
- Epidemiology of glioblastoma in Pakistan: a secondary analysis of the Pakistan Brain Tumor Epidemiology Study (PBTES).Journal of neuro-oncology · 2025Article
- Drosophila melanogaster as a Model System for Human Glioblastoma.Advances in experimental medicine and biology · 2025Review
- Deciphering the dose-dependent effects of thymoquinone on cellular proliferation and transcriptomic changes in A172 glioblastoma cells.PloS one · 2025Article
- Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas.Viruses · 2024Review
- Review
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM) is one of the most frequently occurring tumors in the central nervous system and the most malignant tumor among gliomas. Despite aggressive treatment including surgery, adjuvant TMZ-based chemotherapy, and radiotherapy, GBM still has a dismal prognosis: the median survival is 14.6 months from diagnosis. To date, many studies report several determinants of resistance to this aggressive therapy: (1) O(6)-methylguanine-DNA methyltransferase (MGMT), (2) the complexity of several altered signaling pathways in GBM, (3) the existence of glioma stem-like cells (GSCs), and (4) the blood-brain barrier. Many studies aim to overcome these determinants of resistance to conventional therapy by using various approaches to improve the dismal prognosis of GBM such as modifying TMZ administration and combining TMZ with other agents, developing novel molecular-targeting agents, and novel strategies targeting GSCs. In this paper, we review up-to-date clinical trials of GBM treatments in order to overcome these 4 hurdles and to aim at more therapeutical effect than conventional therapies that are ongoing or are about to launch in clinical settings and discuss future perspectives.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.